---
title: "ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305860981.md"
description: "The second-line-plus phase III is expected to start imminently, with enrollment planned over ~18 months and a potential early-2029 readout. Frontline development is advancing toward a possible H1 2028 pivotal start, while Graves’ IND timing is early 2027.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-11-17T18:09:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305860981.md)
  - [en](https://longbridge.com/en/news/305860981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305860981.md)
generator: "portal-rs"
---

# ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout

The second-line-plus phase III is expected to start imminently, with enrollment planned over ~18 months and a potential early-2029 readout. Frontline development is advancing toward a possible H1 2028 pivotal start, while Graves’ IND timing is early 2027.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common shares](https://longbridge.com/en/news/306180389.md)
- [What Vertex Pharmaceuticals Shareholders Got Right](https://longbridge.com/en/news/306384920.md)
- [What Elevance Health Holders Got Right](https://longbridge.com/en/news/306380588.md)
- [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md)
- [Should Stronger Oncology Earnings Require Action From McKesson (MCK) Investors?](https://longbridge.com/en/news/306384915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**